acarbose: one bounded, context-dependent signal across receipts

Source literature boundary memo

Research question

Across retrieved source-level receipts for acarbose, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature selector kept acarbose because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Plain-language synthesis

Bounded signal: acarbose is only a source-level context map; the selected receipts do not establish one pooled effect.

Boundary map

• Acarbose improves health and lifespan in aging HET3 mice [primary; 2019] doi:10.1111/acel.12898
  • Finding: significantly increased (3%) in females only at 1,000 ppm
  • Population: female mice
  • Intervention/exposure: acarbose at 1000 ppm
• Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging [primary; 2019] doi:10.1093/gerona/glz177
  • Finding: acarbose and 17-α estradiol do not strongly alter these phenotypes
  • Population: HET3 mice
  • Intervention/exposure: acarbose
  • Comparator: control
• Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats [primary; 2012] doi:10.4236/jdm.2012.21013
  • Finding: acarbose produced 51% decrease in maltose loaded diabetic rats
  • Population: maltose loaded diabetic rats
  • Intervention/exposure: acarbose
  • Comparator: control
• The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome [primary; 2019] doi:10.1128/msphere.00528-18
  • Finding: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.
  • Population: mice fed high-starch diet
  • Intervention/exposure: acarbose at 400 ppm
  • Comparator: control without acarbose
• Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. [primary; 2013] doi:10.1371/journal.pone.0079697
  • Finding: 8-week treatment with acarbose significantly decreased fasting blood glucose.
  • Population: diabetic rats
  • Intervention/exposure: acarbose
  • Comparator: diabetic group

Source synthesis

Bounded signal: acarbose is only a source-level context map; the selected receipts do not establish one pooled effect.

Evidence matrix

Effect-bearing comparison

Outcome family	Receipt	Evidence role	Population/setting	Metric	Extracted finding
outcome-specific	Acarbose improves health and lifespan in aging HET3 mice	directionally favorable	female mice	-	significantly increased (3%) in females only at 1,000 ppm
outcome-specific	Effect of quercetin on postprandial glucose excursion after mono- and...	directionally favorable	maltose loaded diabetic rats	-	acarbose produced 51% decrease in maltose loaded diabetic rats
outcome-specific	Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in...	directionally favorable	diabetic rats	-	8-week treatment with acarbose significantly decreased fasting blood glucose

Context-only receipts

Outcome family	Receipt	Evidence role	Population/setting	Metric	Extracted finding
outcome-specific	Life-span Extension Drug Interventions Affect Adipose Tissue...	other/mixed	HET3 mice	-	acarbose and 17-α estradiol do not strongly alter these phenotypes
outcome-specific	The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible...	other/mixed	mice fed high-starch diet	-	a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota...

This receipt-backed scoping note has one bounded signal: acarbose shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2012-2019). Evidence role grouping: direction-bearing receipts: 3; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 2 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging: acarbose and 17-α estradiol do not strongly alter these phenotypes; directionally favorable: Acarbose improves health and lifespan in aging HET3 mice: significantly increased (3%) in females only at 1,000 ppm.

Directional grouping

• directionally favorable: acarbose is the intervention/exposure and the reported clinical endpoint favors that arm.

• comparator/not favorable: acarbose is the comparator arm; the label is limited to that head-to-head endpoint.

• economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.

• non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.

• null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

• directionally favorable: Acarbose improves health and lifespan in aging HET3 mice — significantly increased (3%) in females only at 1,000 ppm

• other/mixed: Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging — acarbose and 17-α estradiol do not strongly alter these phenotypes

• directionally favorable: Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats — acarbose produced 51% decrease in maltose loaded diabetic rats

• other/mixed: The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome — a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.

• directionally favorable: Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. — 8-week treatment with acarbose significantly decreased fasting blood glucose.

Evidence role summary: direction-bearing receipts: 3; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 2 excluded from effect support. Direction labels for audit: directionally favorable: 3 receipt(s) | other/mixed: 2 receipt(s).

Specific moderators in this bundle are population/indication (HET3 mice; diabetic rats; female mice; maltose loaded diabetic rats; mice fed high-starch diet), study design/evidence type (primary).

Context separation

Population/settings are separated as receipt context: HET3 mice, diabetic rats, female mice, maltose loaded diabetic rats, and mice fed high-starch diet. The selected receipts group because each carries a fact-level extraction for acarbose; they separate by context (animal model) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for acarbose: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies. The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain longevity_research is publication-lane metadata only; the source scope here is defined by the selected acarbose receipts.

What would weaken this

• This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts.

Next gaps

No source in this selected bundle tests human clinical endpoints. A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome. If acarbose is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning animal model.